INS and metabolic dysfunction-associated steatotic liver disease: In mice, daidzein may ameliorate insulin resistance in obesity via direct modulation of hepatic ab initio adipogenesis and insulin signaling, and alter adipocyte metabolism to indirectly control obesity and reduce NAFLD by regulating adipokine expression through PPAR γ (50, 51).